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Abstract Each human intestine harbours not only hundreds
of trillions of bacteria but also bacteriophage particles,
viruses, fungi and archaea, which constitute a complex
and dynamic ecosystem referred to as the gut microbiota.
An increasing number of data obtained during the last
10 years have indicated changes in gut bacterial composi-
tion or function in type 2 diabetic patients. Analysis of this
‘dysbiosis’ enables the detection of alterations in specific
bacteria, clusters of bacteria or bacterial functions associat-
ed with the occurrence or evolution of type 2 diabetes; these
bacteria are predominantly involved in the control of in-
flammation and energy homeostasis. Our review focuses
on two key questions: does gut dysbiosis truly play a role
in the occurrence of type 2 diabetes, and will recent discov-
eries linking the gut microbiota to host health be helpful for
the development of novel therapeutic approaches for type 2
diabetes? Here we review how pharmacological, surgical
and nutritional interventions for type 2 diabetic patients
may impact the gut microbiota. Experimental studies in
animals are identifying which bacterial metabolites and
components act on host immune homeostasis and glucose
metabolism, primarily by targeting intestinal cells involved
in endocrine and gut barrier functions. We discuss novel
approaches (e.g. probiotics, prebiotics and faecal transfer)
and the need for research and adequate intervention studies
to evaluate the feasibility and relevance of these new ther-
apies for the management of type 2 diabetes.
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Abbreviations
AX Arabinoxylans
AXOS Arabinoxylan oligosaccharides
BSH Bile salt hydrolase
DIO Diet-induced obesity
FGF19 Fibroblast growth factor 19
GLP Glucagon-like peptide
GPR G protein-coupled receptor
HFD High-fat diet
ITF Inulin-type fructans
LPS Lipopolysaccharides
PRR Pattern recognition receptor
PYY Peptide YY
RYGB Roux-en-Y gastric bypass
SCFA Short-chain fatty acid
TLR Toll-like receptors
TGR5 Transmembrane G protein-coupled receptor 5
VSG Vertical sleeve gastrectomy
Introduction
The onset of type 2 diabetes is clearly associated with both host
genetics and environmental factors (e.g. diet, physical activity).
Emerging evidence indicates that the risk of developing type 2
diabetes may involve a particular environmental factor, specifi-
cally, the collection of microorganisms that inhabit our intestine.
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Each human intestine harbours not only hundreds of trillions of
bacteria, but also bacteriophage particles, viruses, fungi and
archaea, which constitute a complex and dynamic ecosystem
with which we live in symbiosis throughout our lifetime [1].
Given that host genetics is thought to contribute to the profile
of the gut microbiome, all living conditions, including dietary
habits, exposure to xenobiotics (such as drugs, toxicants and
additives) or stresses (such as surgery and infections) will mod-
ulate the gutmicrobiota, occasionally for a limited period of time
due to the resilience of this ecosystem [2]. This review starts
with a description of the human studies relating the changes in
the gut microbiota to glycaemia in type 2 diabetic patients.
Dysbiosis related to type 2 diabetes
and hyperglycaemia
Several clinical trials are ongoing to obtain more precise and
more reliable information about the changes in the composi-
tion and function of the gut microbiota that may be specifical-
ly associated with hyperglycaemia and type 2 diabetes, inde-
pendently of other contributing factors (e.g. body weight)
(for a recent review, see [3]).
Metagenomic data have revealed that patients with type 2
diabetes exhibit a moderate degree of gut microbial dysbiosis
compared with patients with inflammatory bowel disease [4].
The proportions of the phylum Firmicutes and the class Clos-
tridia are significantly reduced, whereas the class of the gram-
negative Betaproteobacteria is highly enriched in the faeces of
type 2 diabetic patients compared with non-diabetic individ-
uals, and the proportion of Betaproteobacteria is positively
correlated with plasma glucose levels [5].
Interestingly, the microbiome of type 2 diabetic patients are
characterised by the depletion of several butyrate-producing
bacteria, including Clostridium species, Eubacterium rectale,
Faecalibacterium prausnitzii, Roseburia intestinalis and
Roseburia inulinivorans [4, 6, 7], and an enrichment of op-
portunistic pathogens [4]. Bacteria increased in the gut of type
2 diabetic patients also include the sulphate-reducing bacteria
Desulfovibrio, as well as Lactobacillus gasseri, Lactobacillus
reuteri and Lactobacillus plantarum [6, 7]. Curiously, the
treatment of Japanese type 2 diabetic patients with
α-glucosidase inhibitors has been shown to increase
Lactobacillus spp. [7]. In accordance with these findings, an
increasing number of observational studies have reported
changes in the gut microbiota associated with type 2 diabetes,
but the outcomes are not always concordant. Zhang et al found
a decreased abundance of Akkermansia muciniphila, a mucus-
colonising bacterium that plays a role in gut barrier function,
in diabetic and glucose-intolerant patients [8]; this observation
has been reported in several studies of obese individuals. Data
on a Chinese population indicated the opposite effect, specif-
ically, an increase in A. muciniphila in type 2 diabetic patients
[4]. Thus, it appears that genetic background and/or medica-
tion can influence the gut microbiota, which might explain
discrepancies between studies.
Many articles have reported a correlation between changes
in the gut microbiota and markers of type 2 diabetes.
Lactobacillus species correlate positively with fasting glucose
and HbA1c levels whereas Clostridium species correlate neg-
atively with fasting glucose, HbA1c and insulin levels [6]. A
recent study suggests that a higher blood glucose concentra-
tion may be predicted by a reduction in the proportion of
anaerobes, particularly Bacteroides [9].
Importantly, different features of metabolic disorders, in-
cluding markers of glucose metabolism disorders
(i.e. insulinaemia and HOMA-IR), but not BMI or body
weight, are significantly associated with the gene count of
the microbiome, suggesting that individuals with a low gene
count are characterised by metabolic disturbances known to
increase the risk of diabetes [10].
The functions of the microbiome are also affected in type 2
diabetic patients, such as an increase in membrane transport of
sugars or branched amino acids, the activity of enzymes in-
volved in xenobiotic or carbohydrate metabolism, or sulphate
reduction [4, 6]. In contrast, functions involved in cell motility,
butyrate synthesis and cofactor and vitamin metabolism are
decreased in type 2 diabetic patients [4, 6]. Importantly, markers
related to oxidative stress resistance are also enriched in type 2
diabetic patients, suggesting a type 2 diabetes-associated in-
crease in defence mechanisms in the gut microbiota [4, 6].
Important questions remain unanswered regarding the long-
term persistence of the changes specifically associated with
diabetes and the cause–effect relationship of dysbiosis with
the occurrence or progression of type 2 diabetes in humans.
Clearly, because the alterations in glucose metabolism can be
transmitted by gut microbiota transfer in germ-free mice [11],
some gut microbial populations/functions may play an active
role in the pathogenesis of glucose metabolism disorders. For
evident ethical reasons, the ‘transfer’ of the diabetic phenotype
via the gut microbiota has never been tested in humans.
Bacterial components and metabolites prone
to interact with glucose homeostasis: an overview
of the molecular mechanisms underlying
microbe–host interactions in the context of diabetes
A chronic low-grade inflammation in type 2 diabetes appears
to be a driver of metabolic alterations linked to obesity. The
inflammation in the different tissues contributes to insulin re-
sistance. The triggers of the inflammatory response include
endoplasmic reticulum stress, inflammasome activation and
Toll-like receptors (TLRs). The involvement of TLRs impli-
cates a response to bacterial elements present in the gut
microbiota [12, 13].
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Bacterial components involved in diabetes Gut microbes
are able to communicate with the host via specific cell
membranes or related molecules that may activate pattern
recognition receptors (PRRs). These PRRs are involved in
the recognition of molecular patterns (known as pathogen-
associated molecular patterns or PAMPs) that are specific
to bacteria and other microorganisms. The most studied
PRRs are the TLRs. It is understood that the stimulation
of TLR-4 by bacterial lipopolysaccharides (LPS) results in
an inflammatory response, cytokine production and
chemokine-mediated recruitment of acute inflammatory
cells [14]. In 2007, our laboratory first discovered that
the gut microbiota also contributes to the onset of insulin
resistance and type 2 diabetes via mechanisms associated
with an increase in plasma LPS, defined as metabolic
endotoxaemia [15]. In experimental obesity and type 2
diabetes, metabolic endotoxaemia is associated with an
altered composition of the gut microbiota and with in-
creased intestinal permeability [15–17]. Several human
studies also reported an increase in LPS or LPS-binding
protein levels in association with type 2 diabetes [18].
Taken together, these data highlight a strong relationship
between the gut microbiota, inflammation and metabolic
perturbations, including hyperglycaemia. More recently,
we discovered that specifically inactivating a protein of
the innate immune system that is involved in the signal-
ling of most TLRs (i.e. deleting the protein myeloid dif-
ferentiation primary response gene 88 [MyD88]) in intes-
tinal cells induces body weight loss and improves type 2
diabetes associated with obesity in mice fed a high-fat diet
(HFD). Importantly, this phenomenon is mediated by gut
microbiota-dependent mechanisms, and these data clearly
suggest that intestinal cell walls play a crucial role in the
systemic metabolic response to bacterial elements [19].
The efficacy of the gut barrier is controlled by numerous
pathways and cell types, including mucus-producing gob-
let cells, tight junction proteins, the endocannabinoid sys-
tem and immune responses [20]. In addition, other bacte-
rial components, such as peptidoglycans, which bind
nucleotide-binding oligomerisation domain-containing
protein 2 (NOD2) receptors, are likely to play a protective
role in the control of insulin resistance and obesity. In-
deed, experimental data have recently shown that inhibi-
tion of peptidoglycan signalling in Nod2−/− mice fed an
HFD provokes dysbiosis and promotes bacterial adher-
ence in the mucosae and bacterial accumulation in the
liver, thereby contributing to systemic inflammation, in-
sulin resistance and adiposity [21]. Similarly, TLR5-
deficient mice, which lose their response to bacterial fla-
gellin in the intestinal mucosa, show mild loss of
glycaemic control, which is likely to be driven by insulin
resistance and partially compensated for by increased in-
sulin production—conditions typically observed in
humans with the metabolic syndrome [11]. In humans, a
nonsense polymorphism (R392X) in TLR5 appears to
protect against obesity but, as consistent with findings in
animals, predisposes individuals to type 2 diabetes [22].
Bacterial metabolites and glucose homeostasisMetabolites
produced by gut microbes may also be related to the develop-
ment, or the control, of insulin resistance and type 2 diabetes.
Most of the data illustrated in Fig. 1 have been obtained using
mouse models of diabetes and obesity. As explained below,
several metabolites canmodulate the endocrine function of the
gut, potentially affecting glucose homeostasis.
Short-chain fatty acids (SCFAs; e.g. butyrate, propionate
and acetate) are among the most widely investigated metabo-
lites produced by the gut microbiota that interfere with host
metabolism. These molecules are produced by the microbial
fermentation of specific oligo- or polysaccharides
(i.e. non-digestible carbohydrates) via distinct metabolic path-
ways [23]. The effect of SCFAs on insulin sensitivity and
energy metabolism is now widely accepted, although various
physiological pathways have been suggested. Indeed, SCFAs
are able to modify the levels of several gut peptides involved
in glucose metabolism, gut barrier function and energy
homeostasis [24–26]. For example, butyrate and propionate
were shown to suppress weight gain in mice with HFD-
induced obesity (DIO), and acetate was shown to reduce food
intake in healthy mice [27, 28]. The majority of the pathways
underlying these effects remain unknown. Several studies
have suggested that the effects of SCFAs are mediated by
the members of a recently identified G protein-coupled recep-
tor family that includes G protein-coupled receptors 43 and 41
(GPR43 and GPR41, respectively) (for a review, see [29]).
The binding of SCFAs to GPR43 and GPR41 increases the
plasma levels of glucagon-like peptide-1 (GLP-1) and peptide
YY (PYY), leading to improved glucose homeostasis and
reduced appetite (for a review, see [30]). Interesting studies
in animals have shown that butyrate activates the expression
of genes involved in intestinal gluconeogenesis via a
cAMP-dependent mechanism, whereas propionate, already
known as a substrate for gluconeogenesis, promotes intestinal
gluconeogenic gene expression via a gut–brain neural circuit
involving GPR41. The subsequent release of glucose into the
portal vein contributes to the regulation of glycaemia and in-
sulin sensitivity [31].
Recent data have indicated that the production of indole, a
metabolite produced by gut bacteria from tryptophan, may
also contribute to the secretion of GLP-1 by intestinal
enteroendocrine cells [32, 33]. Chimerel et al discovered that
indole inhibits voltage-gated K+ channels, thereby changing
the action potential properties of L cells and leading to en-
hanced Ca2+ entry, which acutely triggers GLP-1 secretion
[34]. More importantly, it has been found that over a longer
period of stimulation indole acts as an inhibitor of
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mitochondrial metabolism, resulting in a reduction in the in-
tracellular ATP concentration, which induces the opening of
ATP-sensitive K+ (KATP) channels, thereby hyperpolarising
the plasma membrane and slowing GLP-1 release [34]. Inter-
estingly, we recently demonstrated that among alcoholic indi-
viduals, those with higher gut permeability, higher metabolic
endotoxaemia and low-grade inflammation exhibit a lower
abundance of indole and 3-methyl indole [35]. Taken together,
the discovery that indole may trigger GLP-1 secretion and the
finding that gut barrier function is reinforced by indole, lead us
to suggest that GLP-2 is involved in the control of gut barrier
[36] and that its co-secretion with GLP-1 by L cells may be
controlled by indoles.
Over the last 10 years, studies have demonstrated that not
only are bile acids important in the digestion of dietary lipids,
but they also act as signalling molecules in the context of
energy, glucose and lipid metabolism [37]. A recent study
has reported that pretreatment of DIO mice with antibiotics
(vancomycin and bacitracin), which reduces the levels of the
major bacterial phyla (Bacteroidetes and Firmicutes) in the gut
and changes the production of bacterial metabolites, improves
glucose intolerance and insulin resistance The authors pro-
posed GLP-1 as a mediator of these effects and noted an in-
crease in primary conjugated bile acid (taurocholic acid) levels
as a potential key driver of GLP-1 secretion and a key regu-
lator of host glucose homeostasis [38]. TGR5, a G protein-
coupled receptor primarily localised to intestinal
enteroendocrine cells, is primarily activated by secondary bile
acids produced by the gut microbiota (lithocholic and
deoxycholic acids). Activation of this receptor has been asso-
ciated with improved liver function and glucose tolerance in
obese mice by regulating intestinal GLP-1 production [37, 39,
40] (for a review, see [41]). Interestingly H2S, which can be
produced by bacteria expressing sulphate-reducing enzymes,
may counteract TGR5 activation and exert an inhibitory effect
on GLP-1 and PYY release [42]. Moreover, studies conducted
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Fig. 1 Metabolites produced by gut microbes may be related to the
development or the control of insulin resistance and type 2 diabetes.
The figure presents several pathways by which microbial metabolites
can influence various physiological processes (such as gut barrier func-
tion, appetite, insulin secretion and response and intestinal
gluconeogenesis) and thereby affect glucose homeostasis. For more de-
tails, please refer to the main text. Most of the findings illustrated in the
figure have been obtained using mouse models of diabetes and obesity.
The figure was produced using Servier MedicalArt (www.servier.com).
1°BA, primary bile acids; 2°BA, secondary bile acids
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in mice have demonstrated that the gut microbiota regulate the
expression of fibroblast growth factor 15 (for which the
orthologous protein in humans is fibroblast growth factor 19
[FGF19]) in the gut by activating the farnesoid X receptor—
these hormones are responsible for transmitting bile acid-
induced signals in targeted tissues to regulate weight gain
and insulin resistance [40, 43, 44]. Joyce et al have shown that
promoting the activity of bile salt hydrolase (BSH)—an
enzyme distributed across the major bacterial divisions and
archaea that catalyses the deconjugation of bile acids to pro-
duce secondary bile acids—in the gut microbiota may directly
control body weight, blood cholesterol levels, hepatic lipid
levels and fat mass gain [45]. Interestingly, a recent interven-
tion study involving the administration of a BSH-active
L. reuteri strain to healthy volunteers led to an increase in total
plasma (conjugated and unconjugated) bile acid levels that
correlated with the serum FGF19 levels [46]. The impact of
changing the availability and the profile of bile acids on host
glucose homeostasis remains to be clearly established in
humans, but these metabolites appear to function as important
mediators of host metabolism.
Thus, although the influence of the gut microbiota on
energy metabolism is multifactorial, different targets involv-
ing immunity and/or specific metabolites have been
emphasised in recent studies, clearly demonstrating the ratio-
nale for searching for novel therapeutic targets based on com-
pounds derived from or produced by bacteria.
Potential contribution of the gut microbiota
to the pharmacological or surgical treatment of type
2 diabetes
The discovery of the gut microbiota as a metabolic partner in
the management of type 2 diabetes also led to the publication
of studies investigating whether gut microbes play a role in the
benefits of type 2 diabetes therapies.
Metformin is the most widely used glucose-lowering drug.
However, its mechanism of action remains unclear [47]. A
first clue regarding the involvement of the gastrointestinal
tract in the benefits of metformin came from the observation
that intravenous administration of metformin was unable to
reduce glycaemia [48]. A second clue came from the finding
that the improvement in glucose tolerance induced by metfor-
min was abrogated in mice treated with broad-spectrum anti-
biotics [49]. Strikingly, Shin et al reported that metformin
induced a profound shift in the microbial ecosystem in favour
of Akkermansia spp. and that oral administration of
A. muciniphila improved glucose tolerance [49], thereby
confirming the results obtained at our laboratory [50]. The
authors thus suggested that a modulation of the gut microbiota
(likely an increase in the Akkermansia spp. population) may
contribute to the glucose-lowering effects of metformin. A
few months later, Lee et al confirmed that metformin treat-
ment induces an increase in the A. muciniphila population and
demonstrated a negative correlation between glycaemia and
A. muciniphila abundance. Interestingly, co-incubation of
metformin and mouse stool samples led to an enrichment in
A. muciniphila [51], suggesting that metformin directly inter-
acts with the gut microbiota to foster the growth of
A. muciniphila.
Acarbose, an α-glucosidase inhibitor that is almost exclu-
sively used in Asia, is another type 2 diabetes drugwith effects
that could be related to the gut microbiota. In Chinese patients,
the inclusion of acarbose as part of their glucose-lowering
medicat ion has been reported to increase faecal
Bifidobacterium spp. and reduce LPS levels [52].
Interestingly, new therapeutic agents proposed for the treat-
ment of type 2 diabetes (sitagliptin and exenatide) exploit the
GLP-1 pathway. As mentioned earlier, GLP-1 secretion can also
be stimulated by metabolites produced by the gut microbiota
[25]. Reimer et al demonstrated that co-administration of
sitagliptin and a viscous fermentable fibre, which is broken
down into SCFA, more effectively reduced fasting glycaemia
in obese Zucker rats than either treatment alone [53]. Similar
results were obtained in the same model when this fibre was
combinedwithmetformin orwithmetformin and sitagliptin [54].
Currently, the combination of medical therapy with bariat-
ric surgery (vertical sleeve gastrectomy [VSG] or Roux-en-Y
gastric bypass [RYGB]) appears to more effectively control
glycaemia than medical therapy alone in obese patients with
uncontrolled diabetes [55]. In this context, studies have found
that RYGB restructures the gut microbiota in humans and rats
[56, 57]. Transfer of the gut microbiota of mice that underwent
RYGB to non-operated germ-free mice resulted in weight loss
and decreased fat mass but no change in fasting glycaemia,
providing the first evidence that changes in the gut microbiota
contribute to the metabolic improvements conferred by
RYGB [56]. As explained above, bile acids might link the
gut microbiota to the host. Their levels are modified after
bariatric surgery, and VSG does not improve hyperglycaemia
in mice carrying a targeted genetic deletion of the farnesoid X
receptor, implicating bile acids as bacterial modulators of host
homeostasis in this context [58]. Bile acids are without doubt
very interesting mediators. However, the differences in bile
acid and cholesterol metabolism between mice and humans
make it difficult to translate the data from the animal models to
the human situation.
Novel therapeutic approaches of type 2 diabetes
based on the understanding of gut microbiota–host
interactions
Aside from the classical treatments, the recently recognised
implication of gut microbes in the physiopathology of type 2
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diabetes opens a novel area of research for developing new
strategies to tackle this disease using gut microbes.
Microbiota transfer An original study recently investigated
this approach using an infusion of faecal microbiota from lean
donors to recipients with the metabolic syndrome [59]. The
transfer of a microbiota sample from healthy patients was able
to increase the levels of butyrate-producing bacteria and insu-
lin sensitivity in insulin-resistant recipients [59], thus suggest-
ing that the isolation of the microbiota from faecal content
might be developed as a therapeutic strategy to increase insu-
lin sensitivity in humans. However, this type of experiment
assessing the role of the gut microbiota in the control of dia-
betes in humans is currently a proof-of-concept rather than a
potential therapy. Additional studies are needed to confirm the
lack of harmful effects linked to the transfer of faecal
microorganisms, most of which are unidentified and
uncharacterised at present.
Probiotic approach More specific approaches may also be
considered for type 2 diabetic patients. Probiotics are live
microorganisms that, when administered in adequate
amounts, confer a health benefit to the host (i.e. humans)
[60]. To date, the major probiotic strains that have shown
beneficial effects on glucose metabolism in humans belong
to the Lactobacillus genus (i.e. L. plantarum 299v,
Lactobacillus acidophilus NCFM and L. gasseri SBT2055)
[61–63]. These observations may appear to be discordant, as
some Lactobacillus species have been shown to be increased
in type 2 diabetic patients, as previously discussed. However,
the increase in Lactobacillus species in type 2 diabetes has
never been demonstrated to have a direct impact on the dis-
ease. Moreover, the effects obtained using probiotics are prob-
ably strain-specific; thus, different strains of the same species
may exert distinct effects. Importantly, it could be interesting
to investigate other ‘beneficial’ microorganisms that are de-
creased in diabetic patients.
Among the bacteria that could potentially be used for the
treatment of type 2 diabetes, A. muciniphila appears to be of
particular interest. By administering A. muciniphila MucT
(ATTC BAA-835) in a diet-induced mouse model of type 2
diabetes, we demonstrated the direct beneficial effects of this
bacterium on glucose metabolism [50]. First,A. muciniphila is
able to counteract fasting hyperglycaemia in diet-induced
mouse model of type 2 diabetes by preventing the increase
in G6pc (glucose-6-phosphatase) mRNA expression [50].
This suggests that A. muciniphila thwarts the deleterious in-
crease in gluconeogenesis in diabetic mice. Moreover, admin-
istration of live A. muciniphila alleviates glucose intolerance
in HFD-induced diabetic mice [49, 50]. However, additional
studies are needed to establish whether A. muciniphila can be
used as a probiotic for patients with type 2 diabetes, and
of these, intervention studies in humans are of utmost
importance. Finally, A. muciniphila is probably not the sole
bacterium that could be beneficial for the treatment of these
patients; other bacteria, such as F. prausnitzii, which plays
an important role in the maintenance of the gut barrier and
in the control of inflammation, could also be interesting to
investigate (for a review, see [64]).
Non-bacterial ‘colonisers’ of the gut of potential interest In
addition to the classical probiotic bacteria, several other types
of living organism might contribute to the therapeutic arsenal
for treating hyperglycaemia in the future. Here, we consider
the current knowledge on fungi, archaea and helminths re-
garding their relationship with host glycaemia.
Our understanding of the contribution of the mycobiota
(fungal community) to health and disease remains in its infan-
cy [65]. Our laboratory recently provided the first evidence
supporting the hypothesis that fungi can influence host metab-
olism. The yeast Saccharomyces boulardii changed the gut
microbiota and reduced certain features of the metabolic syn-
drome in genetically obese and diabetic mice. However, this
yeast did not change fasting glycaemia in these mice [66].
Improving our understanding of the mycobiota and its rela-
tionship with the host might lead in the future to the develop-
ment of new therapies for the metabolic syndrome.
The predominant archaeon member in the human gut is
Methanobrevibacter smithii. How this methanogenic
archaeon collaborates with saccharolytic bacteria such as
Bacteroides thetaiotaomicron to metabolise complex carbo-
hydrates was elegantly established almost 10 years ago [67].
This symbiotic association increases adiposity when inoculat-
ed into germ-free mice [67]. In humans, methanogenic
archaea are increased in obese vs lean individuals [68], and
intestinal methane production in obese individuals is associ-
ated with a higher BMI [69]. However, this association cannot
be generalised to all archaea [70], and their relationship with
glycaemia has not been reported.
Helminths are known to induce T helper type 2-oriented
immunity in association with eosinophilia. For this reason,
Nippostrongylus brasiliensis has been used in a mouse model
of DIO to maintain eosinophil homeostasis in adipose tissue,
and this intervention led to reduced adipose macrophage
counts and fasting glucose levels [71]. In accordance with
these results, metabonomic investigation of mice infectedwith
Schistosoma mansoni suggested a stimulation of glycolysis,
which might also contribute to the glucose-lowering effect
associated with helminth infection [72]. Moreover, as hel-
minths influence the gut microbiota (e.g. increased
lactobacilli) [73, 74], we cannot exclude an indirect effect of
helminths on host metabolism via modulation of the gut mi-
crobiota. Voluntary infection with helminths might not consti-
tute an appropriate therapeutic approach to reducing blood
glucose levels. However, unravelling the biological mecha-
nisms underlying the beneficial effects of helminths on
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glucose metabolism (such as the induction of eosinophilia or
the stimulation of the growth of lactobacilli) should reveal
new therapeutic targets and would help to identify how the
gut ecosystem plays a role in the control of host metabolism.
A place for nutrition in the management
of glycaemia-related dysbiosis
Inulin-type fructans Nutrition plays an important role in the
management of diabetes. Indeed, some nutrients are able to
decrease the postprandial glucose response. Cereals, legumes,
fruits and spices are four important food groups that contain
active ingredients (such as dietary fibre and polyphenols) that
are able to reduce glycaemia and insulin responses in humans
[75]. The glucose-lowering effect of fibre intake may depend
on the fibre type, amount and/or source. Dietary inulin-type
fructans (ITF), which are present in various fruits and vegeta-
bles, are fermentable carbohydrates that display prebiotic
properties, as their metabolisation by gut microorganisms
modulates the composition and/or activity of the gut microbi-
ota, thus conferring a beneficial physiological effect on the
host [76]. ITF increase the number of endocrine L cells in
the jejunum and colon of rodents and promote the production
and release of the active forms of GLP-1, thereby decreasing
glycaemia [77–81]. A systematic review conducted to evalu-
ate the effectiveness of dietary ITF on serum glucose in
humans revealed that four out of 13 eligible randomised con-
trolled trials published from 1984 to 2009 reported a decrease
in serum glucose concentrations [82]. Interestingly, in healthy
volunteers, 2 weeks of treatment with ITF (16 g per day)
increased the postprandial release of gut peptides (specifically
GLP-1 and gastric inhibitory peptide), modified eating behav-
iour (increased satiety and decreased energy intake) and de-
creased postprandial glycaemia [83]. One study performed on
a limited number of patients at risk for cardiovascular disease
did not support the effect of ITF on insulin sensitivity [84].
Short-chain-enriched inulin (10 g/day) caused a significant
decrease in the levels of fasting plasma glucose, HbA1c and
inflammatory markers (IL-6, TNF-α and LPS) compared with
maltodextrin in a trial of 52 overweight type 2 diabetes wom-
en over a period of 8 weeks [85]. In a study of the correlations
between glycaemic control by ITF in obese women and gut
bacteria, changes in Clostridium cluster IV group (which was
increased by ITF) were negatively correlated with fasting
glycaemia, insulinaemia and HOMA-IR [86]. In contrast,
changes in Propionibacterium spp., Bacteroides intestinalis
and Bacteroides vulgatus, all three of which were significantly
decreased by prebiotic treatment, were positively correlated
with the changes in glucose homeostasis. Serum LPS levels
were negatively correlated with several bacterial phyla and
species , specif ical ly Firmicutes , Act inobacter ia ,
Bifidobacterium and F. prausnitzii, all of which were
promoted by ITF. The promotion of Bifidobacterium by ITF
is logical since these bacteria express β-fructosidase, but the
other changes, such as the interesting increase in F. prausnitzii,
remain unexplained.
Arabinoxylans Other non-digestible carbohydrates are grad-
ually fermented throughout the colon, and these might have
beneficial health effects by acting as substrates for certain
microbes. Arabinoxylans (AX), the most abundant non-
digestible carbohydrates in wheat, are predominantly present
in bran and aleurone fractions [87, 88]. AX are selectively
degraded in the colon by intestinal bacteria expressing
xylanases and arabinofuranosidases and represent a new class
of prebiotics [89–91]. Table 1 summarises the findings of
studies on AX and AXOS (short-chain AX produced via
enzymatic processing) in animal models and in humans. In
our studies, AX and AXOS supplementation induced caecal
and colon enlargement, increased Bifidobacterium spp.,
Bacteroides/Prevotella spp. and Roseburia spp. and improved
insulin resistance in a diet-induced mouse model of type 2
diabetes [92, 93]. Importantly, correlation analysis revealed
that the Roseburia spp. levels are inversely correlated with
HOMA-IR and inflammatory markers. AXOS increased the
level of GLP-1 and counteracted the HFD-induced increase in
HOMA-IR. In addition, AXOS reduced HFD-induced meta-
bolic endotoxaemia [92]. Most human intervention studies,
including those of type 2 diabetic patients, assessing the ef-
fects of wheat-derived AX(OS) on glucose metabolism dem-
onstrated a decrease in glycaemia (Table 1). Additional studies
are needed to determine whether the effect of AX(OS) on gut
microbiota is linked to the improvement in glucose
homeostasis.
Polyphenols Some phenolic compounds abundant in fruit,
vegetables, chocolate, nuts and beverages (tea, coffee, wine
and soy milk) may be poorly absorbed in the upper part of the
gut and are fermented by bacteria in the colon. Our laboratory
has demonstrated that supplementation with pomegranate peel
extract, which is rich in ellagitannins and anthocyanins, mod-
ulates the gut microbiota in favour of bifidobacteria [94].
Although this effect was accompanied by the reduced expres-
sion of key inflammatory factors, it did not significantly mod-
ify glycaemia or glucose tolerance. Of note, several recent
studies have highlighted the importance of gut microbiota
modulation in the metabolic effects of polyphenols on glucose
homeostasis. One such polyphenol is resveratrol, a natural
phytoalexin present in red grapes, peanuts, and berries that
displays antioxidant and anti-inflammatory properties. In
one study, resveratrol increased GLP-1 production via a mech-
anism that was dependent on the alteration of the intestinal
microbiota and required the GLP-1 receptor to mediate its
antidiabetic effect on DIO mice. In particular, it was shown
that Parabacteroides johnsonii, Alistipes putredinis and
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Bacteroides vulgatus, the levels of which were increased
by HFD treatment, disappeared 5 weeks after resveratrol
supplementation [95]. In another study, mice fed an HFD
supplemented with 4% green tea powder for 8 weeks had a
significantly increased insulin response compared with con-
trol mice [96]. In addition, fasting plasma glucose, insulin and
HOMA-IR levels were lower in mice fed the green tea sup-
plement for 11 or 22weeks. In a third study, the administration
of cranberry extract, which is rich in proanthocyanidins, im-
proved insulin sensitivity in high-fat/high-sucrose diet-fed
mice. In this study, cranberry extract treatment markedly in-
creased the proportion of Akkermansia and decreased intesti-
nal inflammation [97]. Finally, a double-blind trial revealed
that changes in the gut microbiota are associated with the
glucose-lowering effects of a traditional berberine-containing
Chinese herbal formula in type 2 diabetic patients [98]. In-
deed, this decoction significantly increased F. prausnitzii,
which was negatively correlated with fasting blood glucose,
HbA1c and postprandial blood glucose levels and was posi-
tively correlated with HOMA of beta cell function.
Importantly, energy-free artificial sweeteners were exten-
sively introduced to our diets with the intention of reducing
energy intake and normalising blood glucose levels without
‘sweet-toothed’ humans having to compromise. A recent
study demonstrated that the consumption of commonly used
artificial sweetener formulations drives the development of
glucose intolerance via the induction of compositional and
functional alterations to the intestinal microbiota [99]. Wheth-
er the bacterial populations or metabolic pathways altered by
the consumption of artificial sweeteners are similar to those
described in individuals with or developing diabetes remains
to be elucidated [99, 100].
Conclusions
Type 2 diabetes, a complex disease that is often associated
with obesity, develops via the interaction between genetic
and environmental factors. We believe that the gut microbiota
represents an environmental factor of type 2 diabetes that was
neglected in the past due to the complexity of its analysis and
to the lack of an understanding of the mechanisms underlying
the interactions between gut microbes and host metabolism.
The current interest in the gut microbiota as a potential target
for the management of non-communicable diseases such as
type 2 diabetes partially relies on the novel methodologies
available for analysing the composition and function of the
gut microbiota, as well as on the recent discoveries of host
molecular targets that are prone to ‘respond’ to bacterial me-
tabolites/components. To those who might question the rele-
vance of gut dysbiosis in the occurrence of type 2 diabetes, we
would say that all of the data supporting a causative role of
dysbiosis in type 2 diabetes have been obtained using germ-
free animals into which the intestinal content of diabetic mice
was transferred. As far as the development of novel therapeu-
tic approaches is concerned, intervention studies using probi-
otic, prebiotic, or microbial transplantation have been success-
ful in a very limited number of published reports. Nutritional
advice is crucial in the management of diabetes. We believe
that a better characterisation of the nutrients that are able to
modulate the gut microbiota in favour of anti-inflammatory
bacteria or bacterial metabolites is needed to provide adequate
advice to patients who are at risk for type 2 diabetes
development.
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